Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:688013's Debt-to-EBITDA is ranked worse than 61.57% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs SHSE:688013: 2.25
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Touchstone International Medical Science Co Debt-to-EBITDA Related Terms
Touchstone International Medical Science Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Touchstone International Medical Science Co Debt-to-EBITDA Chart
Touchstone International Medical Science Co Annual Data
SHSE:688013 vs ISRG, BDX, RMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Touchstone International Medical Science Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Touchstone International Medical Science Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Touchstone International Medical Science Co (SHSE:688013) has a Debt-to-EBITDA of 5.46 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Touchstone International Medical Science Co. This is 18100% above median its historical median of 0.03. Over the past decade, Touchstone International Medical Science Co's Debt-to-EBITDA has ranged from 0.02 to 2.25. According to the industry distribution chart, Touchstone International Medical Science Co ranks #290 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 61.6%.
Is Touchstone International Medical Science Co's Debt-to-EBITDA too high?
Touchstone International Medical Science Co's current Debt-to-EBITDA of 5.46 is 18100% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.25. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Touchstone International Medical Science Co's value of 5.46 is 235% above this industry median. Based on the distribution chart, Touchstone International Medical Science Co ranks #290 out of 471 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Touchstone International Medical Science Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Touchstone International Medical Science Co's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Touchstone International Medical Science Co ranks #290 out of 471 companies for Debt-to-EBITDA. This places Touchstone International Medical Science Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Touchstone International Medical Science Co's value of 5.46 is 235% above this benchmark. Historically, Touchstone International Medical Science Co's own Debt-to-EBITDA has ranged from 0.02 to 2.25 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 1.63, Touchstone International Medical Science Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Touchstone International Medical Science Co's current Debt-to-EBITDA of 5.46 is 235% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Touchstone International Medical Science Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Touchstone International Medical Science Co's current Debt-to-EBITDA is 5.46, which is 18100% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Touchstone International Medical Science Co stock overvalued right now?
Based on GuruFocus' analysis, Touchstone International Medical Science Co (SHSE:688013) is currently considered Fairly Valued. The stock's GF Value™ is ¥24.29, compared to a current price of ¥24.59 — trading 1.2% above its estimated fair value. The current Debt-to-EBITDA is 5.46, which is 18100% above median its 10-year median of 0.03 and 235% above the Medical Devices & Instruments industry median of 1.63. Touchstone International Medical Science Co's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Touchstone International Medical Science Co (SHSE:688013), the current Debt-to-EBITDA is 5.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Touchstone International Medical Science Co (SHSE:688013) Overvalued in 2026?
Based on GuruFocus' analysis, Touchstone International Medical Science Co stock appears to be overvalued.
The current stock price of ¥24.59 is trading 1.2% above its estimated GF Value™ of ¥24.29.
GuruFocus considers Touchstone International Medical Science Co to be Fairly Valued.
Key valuation signals for SHSE:688013:
Debt-to-EBITDA: 5.46 (18100% above median its 10-year median of 0.03)
GF Value™: ¥24.29 vs. price of ¥24.59 (1.2% above fair value)
Industry Position: 235% above the Medical Devices & Instruments median (#290 of 471)
No single metric tells the full story. See the SHSE:688013 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Touchstone International Medical Science Co Ltd is specialized in the development of surgical staplers that enhance clinical performance, minimise risk and improve patient outcomes. The company's products include Auto Purse String Clamp for Single Use (APS); Intraluminal Stapler for Single Use (CSC&ECSC); Endoscopic Linear Cutter and Single Use Loading Unit (ELC&ELCC); Intraluminal Stapler for Single Use (KOL); Linear Cutter and Reloads (LC&LCC); Linear Stapler and Reloads (LS&LSC); PPH Stapler and Purse Sets for Single Use (PPH); Tissue - Selecting Therapy Stapler (TST33); Tissue - Selecting Therapy Stapler (TST36); and Tissue - Selecting Therapy Stapler (Proctology Examination Kit).
78GF Score
Get the complete analysis for SHSE:688013
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688013 has been successfully added to your 
